Myelodysplastic Syndromes
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors
Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS) are considered precursor diseases to hematologic malignancies,…
Date: 28th March 2024
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms which can be categorized into lower- and higher-risk disease (LR-MDS;…
Date: 8th February 2024
Updates on the diagnosis, risk stratification and treatment of lower-risk MDS
The treatment and management of lower-risk myelodysplastic syndromes (LR-MDS) has remained a challenge in the field, and several studies are…
Date: 6th October 2023
Pre-MDS states: improving prognosis, novel therapeutic approaches, and challenges with distinguishing these conditions
Myelodysplastic syndromes (MDS) represent a heterogeneic group of disorders which remain a challenge to diagnose and treat. In recent years,…
Date: 16th August 2023
MDS 2023 highlights: managing anemia in lower-risk MDS & overcoming treatment failure in higher-risk disease
Therapeutic agents for patients with myelodysplastic syndromes (MDS) are currently under active investigation in clinical trials. The management of cytopenias,…
Date: 31st May 2023
Comparing the ICC and WHO classifications for MDS and their impact on clinical practice
Recently, the International Consensus Classification (ICC) and World Health Organization (WHO) classification systems for myelodysplastic syndromes (MDS) were updated and…
Date: 24th March 2023
Novel immune therapies in MDS and challenges in this space
Myelodysplastic syndromes (MDS) represent a group of heterogeneous diseases which remain a challenge to treat, and several novel therapies are…
Date: 7th February 2023
The importance of CD47 in MDS and other targets of interest
CD47 is a cell surface protein which is overexpressed in several cancer cells and appears to play an important role…
Date: 17th January 2023
Highlights in MDS at ASH 2022: treating lower-risk & higher-risk disease, trial updates, & more
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans,…
Date: 21st December 2022
iwAL 2022 Session III: novel targets, combinations and treatment strategies in AML
The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the…
Date: 16th November 2022
The role of the innate immune system in MDS
Myelodysplastic syndromes (MDS) represent a heterogeneous group of diseases which remain a challenge to treat, and immune dysregulation has been…
Date: 2nd November 2022
iwMDS 2022: Key highlights
The 1st International Workshop on Myelodysplastic Syndromes (iwMDS) 2022 was held in Miami, FL, and brought together leading experts in…
Date: 29th September 2022
